Page 8 - Discovery Engine News Today

The Straits Times The Open Innovation Platform will soon have a new search function on its website.ST PHOTO: KELVIN CHNG https://str.sg/JF7z They can read the article in full after signing up for a free account. Share link: Or share via: Sign up or log in to read this article in full Sign up All done! This article is now fully available for you Read now Get unlimited access to all stories at $0.99/month for the first 3 months. Get unlimited access to all stories at $0.99/month for the first 3 m...

Search jobs RubrYc Therapeutics Announces a Research Collaboration and License Option Agreement With Zai Labs SAN CARLOS, Calif.--(BUSINESS WIRE)--RubrYc Therapeutics, Inc., a pre-clinical biotherapeutics company developing epitope selective therapies, today announced that it has entered into a research collaboration and license option agreement with Zai Labs, Inc. for the use of RubrYc’s Meso-scale Engineered Molecules (MEMs) platform, to identify monoclonal antibodi...

How Singapore is Helping Businesses Accelerate Digital Transformation and Expand Overseas How Singapore is Helping Businesses Accelerate Digital Transformation and Expand Overseas March 9, 2021 Posted by ASEAN Briefing Written by Ayman Falak Medina Reading Time: 4 minutes Singapore has extended several measures to assist businesses in accelerating their digital transformation. The government recognizes that the success of new business models...

Arvinas to Present at the Guggenheim Healthcare Talks: 2021 Oncology Day NEW HAVEN, Conn., Feb. 08, 2021 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that John Houston, Ph.D., President and Chief Executive Officer and Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks: 2021 Oncology Day on Thursday, Feb...

[December 28, 2020] Arvinas, Inc. Announces Exercise of Underwriters Option to Purchase Additional Shares NEW HAVEN, Conn., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its PROTAC ® Discovery Engine, today announced that the underwriters of its previously announced underwritten public offering of common stock, which closed on December 18, 2020, have exercised in...

Share: NEW HAVEN, Conn., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its PROTAC ® Discovery Engine, today announced the pricing of an underwritten public offering of 5,714,286 shares of its common stock at a price of $70.00 per share, before underwriting discounts and commissions. In addition, Arvinas has granted the underwriters an option for a period of 30 day...